Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
39218359
DOI
10.1016/j.jaci.2024.08.020
PII: S0091-6749(24)00903-5
Knihovny.cz E-resources
- Keywords
- Allogeneic HSCT, CTLA-4, abatacept, belatacept, primary immune regulatory disorder,
- MeSH
- CTLA-4 Antigen * genetics MeSH
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Graft vs Host Disease MeSH
- Child, Preschool MeSH
- Retrospective Studies MeSH
- Hematopoietic Stem Cell Transplantation * MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Europe MeSH
- Names of Substances
- CTLA-4 Antigen * MeSH
- CTLA4 protein, human MeSH Browser
BACKGROUND: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) insufficiency causes a primary immune regulatory disorder characterized by lymphoproliferation, dysgammaglobulinemia, and multiorgan autoimmunity including cytopenias and colitis. OBJECTIVE: We examined the outcome of hematopoietic stem cell transplantation (HSCT) for CTLA-4 insufficiency and study the impact of pre-HSCT CTLA-4 fusion protein (CTLA-4-Ig) therapy and pre-HSCT immune dysregulation on survival and immunologic outcome. METHODS: This was a retrospective study of HSCT for CTLA-4 insufficiency and 2q33.2-3 deletion from the European Society for Blood and Marrow Transplantation Inborn Errors Working Party. Primary end points were overall survival (OS) and disease- and chronic graft-versus-host disease-free survival (DFS). Secondary end point was immunologic outcome assessed by immune dysregulation disease activity (IDDA) score. RESULTS: Forty patients were included over a 25-year period. Before HSCT, 60% received CTLA-4-Ig, and median (range) IDDA score was 23.3 (3.9-84.0). Median (range) age at HSCT was 14.2 (1.3-56.0) years. Patients received peripheral blood stem cell (58%) or marrow (43%) from a matched unrelated donor (75%), mismatched unrelated donor (12.5%), or matched family donor (12.5%). Median (range) follow-up was 3 (0.6-15) years, and 3-year OS was 76.7% (58-87%) and DFS was 74.4% (54.9-86.0%). At latest follow-up, disease of 28 of 30 surviving patients was in disease-free remission with median IDDA reduction of 16. Probability of OS and DFS was greater in patients with lower disease activity before HSCT (IDDA < 23, P = .002 and P = .006, respectively). CTLA-4-Ig receipt did not influence OS or DFS. Cause of death was transplant related in 7 of 8 patients. CONCLUSION: HSCT is an effective therapy to prevent ongoing disease progression and morbidity, with improving survival rates over time and in patients with lower pre-HSCT disease activity.
Bone Marrow Transplant Unit Oncology Service Hospital Sant Joan de Déu Barcelona Spain
Department of Haematology and Oncology University Hospital Freiburg Freiburg Germany
Department of Hematology Leiden University Medical Center Leiden The Netherlands
Department of Immunology Newcastle Hospitals NHS Foundation Trust Newcastle upon Tyne United Kingdom
Department of Pediatric Hematology Oncology and BMT Wroclaw Medical University Wroclaw Poland
Paediatric Haematopoietic Stem Cell Transplant Unit University Hospital La Paz Madrid Spain
Paediatric Immunology Royal Hospital for Children Glasgow United Kingdom
Paediatric Stem Cell Transplantation Royal Hospital for Children Glasgow United Kingdom
Stem Cell Transplant Unit Aghia Sophia Children's Hospital Athens Greece
References provided by Crossref.org